Pharmacies sue to stop Pfizer/Wyeth deal

Seven California pharmacies don't want to see Pfizer's $68 billion buyout of Wyeth succeed, and they've filed suit against the drugmaker to protest the deal. Four of the five banks that provided the $22 billion loan to finance the deal were beneficiaries of the Troubled Asset Relief Program funds, claims Golden Gate Pharmacy Services. The group objects to the fact that government bailout money would be used to finance a buyout that will result in the loss of some 22,000 jobs. In addition to job cuts, Golden Gate says the deal will lead to less competition for certain drugs and give pharmacies fewer supplier choices.

A Pfizer spokesperson told Bloomberg that the company hasn't been served with the lawsuit, but believes the complaint, which was filed in a San Francisco federal court, is without merit.

- here's the Bloomberg report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.